MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$4.20
Change
+$0.19 (+4.74%)
Capitalization
805.13M

ABUS stock forecast, quote, news & analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ABUS showed earnings on August 06, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Sep 04, 2025

ABUS in +4.97% Uptrend, rising for three consecutive days on September 04, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABUS advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

ABUS moved above its 50-day moving average on August 04, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABUS crossed bullishly above the 50-day moving average on August 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for ABUS moved above the 200-day moving average on September 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 228 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ABUS broke above its upper Bollinger Band on September 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.699) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (325.279).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.87B. The market cap for tickers in the group ranges from 31.65 to 101.56B. VRTX holds the highest valuation in this group at 101.56B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 15%, and the average quarterly price growth was 33%. MLYS experienced the highest price growth at 125%, while PPBT experienced the biggest fall at -67%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was -46% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 82
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com